Update on Current and Future Management for Diabetic Maculopathy

Patricia Udaondo*, Mariacristina Parravano, Stela Vujosevic, Dinah Zur, Usha Chakravarthy

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Diabetic macular edema (DME) remains the major cause of preventable blindness in the working-age population in developed countries, and screening programs are extremely important in the management of this complication of diabetic retinopathy. The introduction of modern imaging modalities and technological advances have facilitated both the early detection and the follow-up of patients with DME, particularly optical coherence tomography angiography and artificial intelligence. Intravitreal therapy is the gold standard treatment for DME, but not all patients respond equally to this therapy, and sometimes it is not easy to apply treatment protocols correctly; for these reasons, clinical practice results may differ from those of clinical trials in terms of vision gain. One approach has been to implement new treatment regimens, such as treat and extend, and new molecules and therapeutic targets are constantly being developed. The main goal of this review paper is to describe the current treatment options and management strategies for DME in Europe and to provide a brief oversight of the novel therapeutic options on the horizon.

Original languageEnglish
Pages (from-to)489-502
Number of pages14
JournalOphthalmology and Therapy
Issue number2
StatePublished - Apr 2022


  • AntiVEGF
  • Diabetic macular edema
  • Diabetic retinopathy
  • Intravitreal therapy
  • Steroids


Dive into the research topics of 'Update on Current and Future Management for Diabetic Maculopathy'. Together they form a unique fingerprint.

Cite this